
The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals provided perspective on the negative effects seen from quetiapine and how the knowledge of pimavanserin has improved since approval. [WATCH TIME: 5 minutes]
The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals provided perspective on the negative effects seen from quetiapine and how the knowledge of pimavanserin has improved since approval. [WATCH TIME: 5 minutes]
The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals discussed the ongoing challenges with lowering mortality in Parkinson disease, and the need to improve caregiver burden. [WATCH TIME: 4 minutes]
The vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals provided perspective on the mechanistic advantages of pimavanserin over atypical antipsychotics to treat Parkinson disease psychosis. [WATCH TIME: 2 minutes]
Published: August 29th 2025 | Updated: September 2nd 2025
Published: July 28th 2025 | Updated: July 30th 2025
Published: May 14th 2025 | Updated: May 16th 2025
Published: May 12th 2025 | Updated: May 13th 2025
Published: March 27th 2025 | Updated: March 28th 2025
Published: March 4th 2025 | Updated: March 19th 2025